160005-43-6

Basic information

• Product Name: (4-Bromo-thiophen-2-yl)-acetonitrile
• Synonyms: (4-Bromo-thiophen-2-yl)-acetonitrile
• CAS NO: 160005-43-6
• Molecular Formula: C₆H₄BrNS
• Molecular Weight: 202.07166
• Mol File: 160005-43-6.mol

Chemical Properties

• Boiling Point: 289.3°C at 760 mmHg
• Flash Point: 128.8°C
• Appearance: /
• Density: 1.665g/cm³
• Vapor Pressure: 0.00222mmHg at 25°C
• Refractive Index: 1.605
• CAS DataBase Reference: (4-Bromo-thiophen-2-yl)-acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Bromo-thiophen-2-yl)-acetonitrile(160005-43-6)
• EPA Substance Registry System: (4-Bromo-thiophen-2-yl)-acetonitrile(160005-43-6)

Safety Data

• HazardClass: IRRITANT, IRRITANT-HARMFUL
• Hazardous Substances Data: 160005-43-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-Bromo-thiophen-2-yl)-acetonitrile is used as a key intermediate in the synthesis of fused dihydropyridinone derivatives, which are known as Janus Kinase (JAK) inhibitors. These inhibitors play a crucial role in the prevention or treatment of autoimmune diseases by modulating the JAK/STAT signaling pathway, which is often dysregulated in such conditions.

InChI:InChI=1/C6H4BrNS/c7-5-3-6(1-2-8)9-4-5/h3-4H,1H2

Upstream product

• 18791-75-8 4-Bromothiophen-2-aldehyde 
• 79757-77-0 (4-bromothiophen-2-yl)methanol 
• 170859-70-8 4-bromo-2-(chloromethyl)thiophene 
• 151-50-8 potassium cyanide 

Downstream Products

• 917772-62-4 C₂₃H₃₁BrN₂O₄SSi 
• 1192479-41-6 C₂₃H₂₇BrN₄O₃S 
• 917772-60-2 C₁₇H₁₆BrNO₄S 
• 917772-61-3 C₁₈H₁₈BrNO₄S 
• 1192479-39-2 C₁₈H₁₈BrNO₄S*ClH 

Relevant articles and documents

Rapid and Simple Access to α-(Hetero)arylacetonitriles from Gem-Difluoroalkenes

A scalable cyanation of gem-difluoroalkenes to (hetero)arylacetonitrile derivatives was developed. This strategy features mild reaction conditions, excellent yields, wide substrate scope, and broad functional group tolerance. Significantly, in this reacti

Preparation method of aryl acetonitrile derivative

The invention relates to a continuous nucleophilic addition and beta-fluorine elimination reaction method of 2,2-difluoroolefin and ammonia water in a catalyst-free and additive-free system. The method comprises the following steps: adding a 2,2-difluoroolefin compound, ammonia water and a solvent into a Schlenk reaction flask, and conducting stirring and reacting at a certain temperature in an air atmosphere to obtain the product aryl acetonitrile derivative.

Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: Conformational constraint to favor a bioactive conformation

On the basis of our observation that the biaryl substituent of iminopyrimidinone 7 must be in a pseudoaxial conformation to occupy the contiguous S1-S3 subsites of BACE1, we have designed a novel fused bicyclic iminopyrimidinone scaffold intended to favor this bioactive conformation. Strategic incorporation of a nitrogen atom in the new constrained ring allowed us to develop SAR around the S2′ binding pocket and ultimately resulted in analogues with low nanomolar potency for BACE1. In particular, optimization of the prime side substituent led to major improvements in potency by displacement of two conserved water molecules from a region near S2′. Further optimization of the pharmacokinetic properties of this fused pyrrolidine series, in conjunction with facile access to a rat pharmacodynamic model, led to identification of compound 43, which is an orally active, brain penetrant inhibitor that reduces Aβ40 in the plasma, CSF, and cortex of rats in a dose-dependent manner.

THIOPHENYL-SUBSTITUTED 2-IMINO-3-METHYL PYRROLO PYRIMIDINONE COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides provides certain thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidone compounds, including compounds (or tautomers or a pharmaceutically acceptable salts thereof) having the structural Formula (III): wherein R2, R3, R4, R5, R6, R7, R8, and R9 are each selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds, and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's Disease, are also disclosed.

TRIAZOLE DERIVATIVE OR SALT THEREOF

[Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11β-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.

ASPARTYL PROTEASE INHIBITORS

Disclosed are compounds of the formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R1, R2, R3, R4, R6, R7 and R7a are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula (I) in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Stilbene derivative and stilbene analog derivative, and use thereof

The present invention relates to a novel compound having a 12-lipoxygenase inhibitory effect, of the general formula (I), a precursor thereof, and a medicine containing the same, STR1 wherein R1 represents a hydrogen atom or a hydroxy group; on